Overweight Lupin, target price Rs 2,500: Axis Securities
Axis Securities has an overweight call on Lupin with a target price of Rs 2500. The current market price of Lupin Ltd. is Rs 1959. Lupin, incorporated in 1983, is a Large Cap company with a market cap of Rs 90156.51 crore, operating in the Pharmaceuticals sector.
Lupin's key products/revenue segments include Pharmaceuticals, Other Services, Export Incentives, Other Operating Revenue and Scrap for the year ending 31-Mar-2024.
Financials For the quarter ended 31-12-2024, the company has reported a Consolidated Total Income of Rs 5821.42 crore, up 1.86% from last quarter Total Income of Rs 5715.02 crore and up 11.38% from last year same quarter Total Income of Rs 5226.78 crore. The company has reported net profit after tax of Rs 858.86 crore in latest quarter.
The company's top management includes Mrs.Manju D Gupta, Mr.Jeffrey Kindler, Mr.Jean-Luc Belingard, Dr.Punita Kumar-Sinha, Mr.Mark D McDade, Mr.Ramesh Swaminathan, Ms.Vinita Gupta, Mr.Nilesh D Gupta, Mrs.Manju D Gupta, Mr.Alfonso Zulueta, Mr.Jeffrey Kindler, Mr.Jean-Luc Belingard, Dr.Punita Kumar-Sinha, Mr.Mark D McDade, Mr.Ramesh Swaminathan, Ms.Vinita Gupta, Mr.Nilesh D Gupta, Mr.Alfonso Zulueta. Company has B S R & Co. LLP as its auditors. As on 31-12-2024, the company has a total of 46 crore shares outstanding.
Live Events
Investment Rationale
New launches in the US market, such as Darunavir and Spiriva, have gained market shares of up to 30% and 25%, respectively. The recent approval for Megabran has the potential to contribute $50 Mn in annual
